Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of "Moderate Buy" from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given an average rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $38.33.

Several research firms have commented on DNLI. Wedbush decreased their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, August 2nd. Citigroup upped their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a report on Friday, August 2nd. HC Wainwright reiterated a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Wednesday. Bank of America upped their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, July 10th.

Denali Therapeutics Stock Performance

DNLI remained flat at $25.25 during trading on Friday. 695,238 shares of the company were exchanged, compared to its average volume of 1,129,859. The company has a market cap of $3.60 billion, a PE ratio of -26.30 and a beta of 1.40. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $25.90. The business's fifty day moving average price is $23.26 and its 200 day moving average price is $20.80.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to analyst estimates of $10.00 million. Denali Therapeutics's quarterly revenue was down 99.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.30 earnings per share. On average, equities analysts anticipate that Denali Therapeutics will post -2.54 EPS for the current year.

Insider Buying and Selling

In related news, Director Steve E. Krognes sold 30,000 shares of the company's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $22.12, for a total transaction of $663,600.00. Following the completion of the sale, the director now owns 34,404 shares of the company's stock, valued at $761,016.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC lifted its holdings in shares of Denali Therapeutics by 216.7% in the fourth quarter. CWM LLC now owns 2,011 shares of the company's stock worth $43,000 after acquiring an additional 1,376 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Denali Therapeutics by 27.0% in the fourth quarter. Victory Capital Management Inc. now owns 15,348 shares of the company's stock worth $329,000 after acquiring an additional 3,267 shares during the last quarter. Fisher Asset Management LLC bought a new position in shares of Denali Therapeutics in the fourth quarter worth about $59,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Denali Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,006,997 shares of the company's stock worth $21,610,000 after acquiring an additional 25,938 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Denali Therapeutics by 17.7% in the fourth quarter. BNP Paribas Financial Markets now owns 191,643 shares of the company's stock worth $4,113,000 after acquiring an additional 28,817 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.